An Insight on Skin Cancer About Different Targets With Update on Clinical Trials and Investigational Drugs

Dildar, M.; Akram, S.; Irfan, M.; Khan, H.U.; Ramzan, M.; Mahmood, A.R.; Alsaiari, S.A.; Saeed, A.H.M.; Alraddadi, M.O.; Mahnashi, M.H. Skin cancer detection: A review using deep learning techniques. Int. J. Environ. Res. Public Health, 2021, 18(10), 5479.
[http://dx.doi.org/10.3390/ijerph18105479] [PMID: 34065430]

Globocan. 2020. Available from: http://gco.iarc.fr/

National Cancer Institute Melanoma of the Skin-Cancer Stat Facts. Available from: https://seer.cancer.gov/statfacts/html/melan.html [accessed on 10 May 2021]

Saginala, K.; Barsouk, A.; Aluru, J.S.; Rawla, P.; Barsouk, A. Epidemiology of melanoma. Med. Sci., 2021, 9(4), 63.
[http://dx.doi.org/10.3390/medsci9040063] [PMID: 34698235]

Berk-Krauss, J.; Stein, J.A.; Weber, J.; Polsky, D.; Geller, A.C. New systematic therapies and trends in cutaneous melanoma deaths among US whites, 1986-2016. Am. J. Public Health, 2020, 110(5), 731-733.
[http://dx.doi.org/10.2105/AJPH.2020.305567] [PMID: 32191523]

Shalhout, S.Z.; Kaufman, H.L.; Emerick, K.S.; Miller, D.M. Immunotherapy for nonmelanoma skin cancer: Facts and hopes. Clin. Cancer Res., 2022, 28(11), 2211-2220.
[http://dx.doi.org/10.1158/1078-0432.CCR-21-2971] [PMID: 35121622]

Zambrano-Román, M.; Padilla-Gutiérrez, J.R.; Valle, Y.; Muñoz-Valle, J.F.; Valdés-Alvarado, E. Non-melanoma skin cancer: A genetic update and future perspectives. Cancers, 2022, 14(10), 2371.
[http://dx.doi.org/10.3390/cancers14102371] [PMID: 35625975]

Available from: www.cancer.net

Khan, N.H.; Mir, M.; Qian, L.; Baloch, M.; Ali Khan, M.F.; Rehman, A.; Ngowi, E.E.; Wu, D.D.; Ji, X.Y. Skin cancer biology and barriers to treatment: Recent applications of polymeric micro/nanostructures. J. Adv. Res., 2022, 36, 223-247.
[http://dx.doi.org/10.1016/j.jare.2021.06.014] [PMID: 35127174]

Dorrell, D.N.; Strowd, L.C. Skin cancer detection technology. Dermatol. Clin., 2019, 37(4), 527-536.
[http://dx.doi.org/10.1016/j.det.2019.05.010] [PMID: 31466592]

Jain, R.; Sarode, I.; Singhvi, G.; Dubey, S.K. Nanocarrier based topical drug delivery- a promising strategy for treatment of skin cancer. Curr. Pharm. Des., 2020, 26(36), 4615-4623.
[http://dx.doi.org/10.2174/1381612826666200826140448] [PMID: 32851954]

Levine, D.; Fisher, D.E. Current status of diagnostic and prognostic markers in melanoma. Methods Mol. Biol., 2014, 1102, 177-197.
[http://dx.doi.org/10.1007/978-1-62703-727-3_11] [PMID: 24258980]

Singh, A. Nimisha, Novel nanolipoidal systems for the management of skin cancer. Recent Pat. Drug Deliv. Formul., 2020, 14(2), 108-125.
[http://dx.doi.org/10.2174/1872211314666200817115700] [PMID: 32807069]

Krishnan, V.; Mitragotri, S. Nanoparticles for topical drug delivery: Potential for skin cancer treatment. Adv. Drug Deliv. Rev., 2020, 153, 87-108.
[http://dx.doi.org/10.1016/j.addr.2020.05.011] [PMID: 32497707]

Germolec, D.R.; Shipkowski, K.A.; Frawley, R.P.; Evans, E. Markers of inflammation. Methods Mol. Biol., 2018, 1803, 57-79.
[http://dx.doi.org/10.1007/978-1-4939-8549-4_5] [PMID: 29882133]

Tang, L.; Wang, K. Chronic inflammation in skin malignancies. J. Mol. Signal., 2016, 11, 2.
[http://dx.doi.org/10.5334/1750-2187-11-2] [PMID: 31051015]

Mueller, M.M. Inflammation in epithelial skin tumours: Old stories and new ideas. Eur. J. Cancer, 2006, 42(6), 735-744.
[http://dx.doi.org/10.1016/j.ejca.2006.01.014] [PMID: 16527478]

Hensler, S.; Mueller, M.M. Inflammation and skin cancer: Old pals telling new stories. Cancer J., 2013, 19(6), 517-524.
[http://dx.doi.org/10.1097/PPO.0000000000000010] [PMID: 24270351]

Neagu, M.; Constantin, C.; Caruntu, C.; Dumitru, C.; Surcel, M.; Zurac, S. Inflammation: A key process in skin tumorigenesis. Oncol. Lett., 2019, 17(5), 4068-4084.
[PMID: 30944600]

Lund, A.W.; Medler, T.R.; Leachman, S.A.; Coussens, L.M. Lymphatic vessels, inflammation, and immunity in skin cancer. Cancer Discov., 2016, 6(1), 22-35.
[http://dx.doi.org/10.1158/2159-8290.CD-15-0023] [PMID: 26552413]

Maru, G.B.; Gandhi, K.; Ramchandani, A.; Kumar, G. The role of inflammation in skin cancer. Adv. Exp. Med. Biol., 2014, 816, 437-469.
[http://dx.doi.org/10.1007/978-3-0348-0837-8_17] [PMID: 24818733]

Singh, N.; Baby, D.; Rajguru, J.; Patil, P.; Thakkannavar, S.; Pujari, V. Inflammation and cancer. Ann. Afr. Med., 2019, 18(3), 121-126.
[http://dx.doi.org/10.4103/aam.aam_56_18] [PMID: 31417011]

Gordon, R. Skin cancer: An overview of epidemiology and risk factors. Semin. Oncol. Nurs., 2013, 29(3), 160-169.
[http://dx.doi.org/10.1016/j.soncn.2013.06.002] [PMID: 23958214]

D’Orazio, J.; Jarrett, S.; Amaro-Ortiz, A.; Scott, T. UV radiation and the skin. Int. J. Mol. Sci., 2013, 14(6), 12222-12248.
[http://dx.doi.org/10.3390/ijms140612222] [PMID: 23749111]

Linares, M.A.; Zakaria, A.; Nizran, P. Skin cancer. Prim. Care, 2015, 42(4), 645-659.
[http://dx.doi.org/10.1016/j.pop.2015.07.006] [PMID: 26612377]

Saladi, R.N.; Persaud, A.N. The causes of skin cancer: A comprehensive review. Med. Actual., 2005, 41(1), 37-53.
[http://dx.doi.org/10.1358/dot.2005.41.1.875777] [PMID: 15753968]

Wheless, L.; Jacks, S.; Mooneyham, P.K.A.; Leach, B.C.; Cook, J. Skin cancer in organ transplant recipients: More than the immune system. J. Am. Acad. Dermatol., 2014, 71(2), 359-365.
[http://dx.doi.org/10.1016/j.jaad.2014.02.039] [PMID: 24725477]

Paver, E.C.; Currie, A.M.; Gupta, R.; Dahlstrom, J.E. Human papilloma virus related squamous cell carcinomas of the head and neck: diagnosis, clinical implications and detection of HPV. Pathology, 2020, 52(2), 179-191.
[http://dx.doi.org/10.1016/j.pathol.2019.10.008] [PMID: 31889547]

Li, C.; Athar, M. Ionizing radiation exposure and basal cell carcinoma pathogenesis. Radiat. Res., 2016, 185(3), 217-228.
[http://dx.doi.org/10.1667/RR4284.S1] [PMID: 26930381]

Doré, J.F.; Chignol, M.C. Tanning salons and skin cancer. Photochem. Photobiol. Sci., 2012, 11(1), 30-37.
[http://dx.doi.org/10.1039/c1pp05186e] [PMID: 21845253]

Gutzmer, R.; Wiegand, S.; Kölbl, O.; Wermker, K.; Heppt, M.; Berking, C. Actinic keratosis and cutaneous squamous cell carcinoma. Dtsch. Arztebl. Int., 2019, 116(37), 616-626.
[http://dx.doi.org/10.3238/arztebl.2019.0616] [PMID: 32048593]

Friedl, P.; Wolf, K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat. Rev. Cancer, 2003, 3(5), 362-374.
[http://dx.doi.org/10.1038/nrc1075] [PMID: 12724734]

Veiseh, O.; Kievit, F.M.; Ellenbogen, R.G.; Zhang, M. Cancer cell invasion: Treatment and monitoring opportunities in nanomedicine. Adv. Drug Deliv. Rev., 2011, 63(8), 582-596.
[http://dx.doi.org/10.1016/j.addr.2011.01.010] [PMID: 21295093]

Harlozinska, A. Progress in molecular mechanisms of tumor metastasis and angiogenesis. Anticancer Res., 2005, 25(5), 3327-3333.
[PMID: 16101146]

Entschladen, F.; Drell, T.L., IV; Lang, K.; Joseph, J.; Zaenker, K.S. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol., 2004, 5(4), 254-258.
[http://dx.doi.org/10.1016/S1470-2045(04)01431-7] [PMID: 15050959]

Chou, Y.P.; Lin, Y.K.; Chen, C.H.; Fang, J.Y. Recent advances in polymeric nanosystems for treating cutaneous melanoma and its metastasis. Curr. Pharm. Des., 2017, 23(35), 5301-5314.
[PMID: 28699537]

Bobos, M. Histopathologic classification and prognostic factors of melanoma: A 2021 update. Ital. J. Dermatol. Venereol., 2021, 156(3), 300-321.
[http://dx.doi.org/10.23736/S2784-8671.21.06958-3] [PMID: 33982546]

Elder, D.E.; Bastian, B.C.; Cree, I.A.; Massi, D.; Scolyer, R.A. The 2018 world health organization classification of cutaneous, mucosal, and uveal melanoma: Detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch. Pathol. Lab. Med., 2020, 144(4), 500-522.
[http://dx.doi.org/10.5858/arpa.2019-0561-RA] [PMID: 32057276]

Yeh, I.; Bastian, B.C. Melanoma pathology: New approaches and classification. Br. J. Dermatol., 2021, 185(2), 282-293.
[http://dx.doi.org/10.1111/bjd.20427] [PMID: 34060071]

Rebecca, V.W.; Sondak, V.K.; Smalley, K.S.M. A brief history of melanoma. Melanoma Res., 2012, 22(2), 114-122.
[http://dx.doi.org/10.1097/CMR.0b013e328351fa4d] [PMID: 22395415]

Savoia, P.; Fava, P.; Casoni, F.; Cremona, O. Targeting the ERK signaling pathway in melanoma. Int. J. Mol. Sci., 2019, 20(6), 1483.
[http://dx.doi.org/10.3390/ijms20061483] [PMID: 30934534]

Mehnert, J.M.; Kluger, H.M. Driver mutations in melanoma: Lessons learned from bench-to-bedside studies. Curr. Oncol. Rep., 2012, 14(5), 449-457.
[http://dx.doi.org/10.1007/s11912-012-0249-5] [PMID: 22723080]

Jager, M.J.; Shields, C.L.; Cebulla, C.M.; Abdel-Rahman, M.H.; Grossniklaus, H.E.; Stern, M.H.; Carvajal, R.D.; Belfort, R.N.; Jia, R.; Shields, J.A.; Damato, B.E. Uveal melanoma. Nat. Rev. Dis. Primers, 2020, 6(1), 24.
[http://dx.doi.org/10.1038/s41572-020-0158-0] [PMID: 32273508]

Cleaver, J. Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum. J. Dermatol. Sci., 2000, 23(1), 1-11.
[http://dx.doi.org/10.1016/S0923-1811(99)00088-2] [PMID: 10699759]

Davis, L.E.; Shalin, S.C.; Tackett, A.J. Current state of melanoma diagnosis and treatment. Cancer Biol. Ther., 2019, 20(11), 1366-1379.
[http://dx.doi.org/10.1080/15384047.2019.1640032] [PMID: 31366280]

Valko-Rokytovska, M.; Bruchata, K.; Simkova, J.; Milkovicova, M.; Kostecka, Z. Current trends in the treatment of malignant melanoma. Neoplasma, 2016, 63(3), 333-341.
[http://dx.doi.org/10.4149/301_151015N533] [PMID: 26925781]

Bradish, J.R.; Cheng, L. Molecular pathology of malignant melanoma: Changing the clinical practice paradigm toward a personalized approach. Hum. Pathol., 2014, 45(7), 1315-1326.
[http://dx.doi.org/10.1016/j.humpath.2014.04.001] [PMID: 24856851]

Mackiewicz, J.; Mackiewicz, A. BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Contemp. Oncol., 2018, 2018(1), 68-72.
[http://dx.doi.org/10.5114/wo.2018.73890] [PMID: 29628797]

Ascierto, P.A.; Kirkwood, J.M.; Grob, J.J.; Simeone, E.; Grimaldi, A.M.; Maio, M.; Palmieri, G.; Testori, A.; Marincola, F.M.; Mozzillo, N. The role of BRAF V600 mutation in melanoma. J. Transl. Med., 2012, 10(1), 85.
[http://dx.doi.org/10.1186/1479-5876-10-85] [PMID: 22554099]

Menzies, A.M.; Long, G.V. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin. Cancer Res., 2014, 20(8), 2035-2043.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-2054] [PMID: 24583796]

Shirley, M. Encorafenib and binimetinib: First global approvals. Drugs, 2018, 78(12), 1277-1284.
[http://dx.doi.org/10.1007/s40265-018-0963-x] [PMID: 30117021]

Chopra, N.; Nathan, P.D. Trametinib in metastatic melanoma. Expert Rev. Anticancer Ther., 2015, 15(7), 749-760.
[http://dx.doi.org/10.1586/14737140.2015.1060127] [PMID: 26107021]

Signorelli, J.; Shah Gandhi, A. Cobimetinib. Ann. Pharmacother., 2017, 51(2), 146-153.
[http://dx.doi.org/10.1177/1060028016672037] [PMID: 27701080]

Attwa, M.W.; Darwish, H.W.; Al-Shakliah, N.S.; Kadi, A.A. A validated LC–MS/MS assay for the simultaneous quantification of the FDA-approved anticancer mixture (Encorafenib and Binimetinib): Metabolic stability estimation. Molecules, 2021, 26(9), 2717.
[http://dx.doi.org/10.3390/molecules26092717] [PMID: 34063139]

Patel, H.; Yacoub, N.; Mishra, R.; White, A.; Yuan, L.; Alanazi, S.; Garrett, J.T. Current advances in the treatment of BRAF-mutant melanoma. Cancers, 2020, 12(2), 482.
[http://dx.doi.org/10.3390/cancers12020482] [PMID: 32092958]

Patrinely, J.R., Jr; Baker, L.X.; Davis, E.J.; Song, H.; Ye, F.; Johnson, D.B. Outcomes after progression of disease with anti–PD1/PD‐L1 therapy for patients with advanced melanoma. Cancer, 2020, 126(15), 3448-3455.
[http://dx.doi.org/10.1002/cncr.32984] [PMID: 32463489]

Namikawa, K.; Yamazaki, N. Targeted therapy and immunotherapy for melanoma in Japan. Curr. Treat. Options Oncol., 2019, 20(1), 7.
[http://dx.doi.org/10.1007/s11864-019-0607-8] [PMID: 30675668]

Lopez, A. Molecular mechanisms and biomarkers of skin photocarcinogenesis. Human Skin Cancers; Miroslav, B., Ed.; , 2018.
[http://dx.doi.org/10.5772/intechopen.70879]

Trager, M.H.; Geskin, L.J.; Samie, F.H.; Liu, L. Biomarkers in melanoma and non-melanoma skin cancer prevention and risk stratification. Exp. Dermatol., 2022, 31(1), 4-12.
[http://dx.doi.org/10.1111/exd.14114] [PMID: 32415889]

Krauthammer, M.; Kong, Y.; Ha, B.H.; Evans, P.; Bacchiocchi, A.; McCusker, J.P.; Cheng, E.; Davis, M.J.; Goh, G.; Choi, M.; Ariyan, S.; Narayan, D.; Dutton-Regester, K.; Capatana, A.; Holman, E.C.; Bosenberg, M.; Sznol, M.; Kluger, H.M.; Brash, D.E.; Stern, D.F.; Materin, M.A.; Lo, R.S.; Mane, S.; Ma, S.; Kidd, K.K.; Hayward, N.K.; Lifton, R.P.; Schlessinger, J.; Boggon, T.J.; Halaban, R. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet., 2012, 44(9), 1006-1014.
[http://dx.doi.org/10.1038/ng.2359] [PMID: 22842228]

Akbani, R.; Akdemir, K.C.; Aksoy, B.A.; Albert, M.; Ally, A.; Amin, S.B.; Arachchi, H.; Arora, A.; Auman, J.T.; Ayala, B.; Baboud, J.; Balasundaram, M.; Balu, S.; Barnabas, N.; Bartlett, J.; Bartlett, P.; Bastian, B.C.; Baylin, S.B.; Behera, M.; Belyaev, D.; Benz, C.; Bernard, B.; Beroukhim, R.; Bir, N.; Black, A.D.; Bodenheimer, T.; Boice, L.; Boland, G.M.; Bono, R.; Bootwalla, M.S.; Bosenberg, M.; Bowen, J.; Bowlby, R.; Bristow, C.A.; Brockway-Lunardi, L.; Brooks, D.; Brzezinski, J.; Bshara, W.; Buda, E.; Burns, W.R.; Butterfield, Y.S.N.; Button, M.; Calderone, T.; Cappellini, G.A.; Carter, C.; Carter, S.L.; Cherney, L.; Cherniack, A.D.; Chevalier, A.; Chin, L.; Cho, J.; Cho, R.J.; Choi, Y-L.; Chu, A.; Chudamani, S.; Cibulskis, K.; Ciriello, G.; Clarke, A.; Coons, S.; Cope, L.; Crain, D.; Curley, E.; Danilova, L.; D’Atri, S.; Davidsen, T.; Davies, M.A.; Delman, K.A.; Demchok, J.A.; Deng, Q.A.; Deribe, Y.L.; Dhalla, N.; Dhir, R.; DiCara, D.; Dinikin, M.; Dubina, M.; Ebrom, J.S.; Egea, S.; Eley, G.; Engel, J.; Eschbacher, J.M.; Fedosenko, K.V.; Felau, I.; Fennell, T.; Ferguson, M.L.; Fisher, S.; Flaherty, K.T.; Frazer, S.; Frick, J.; Fulidou, V.; Gabriel, S.B.; Gao, J.; Gardner, J.; Garraway, L.A.; Gastier-Foster, J.M.; Gaudioso, C.; Gehlenborg, N.; Genovese, G.; Gerken, M.; Gershenwald, J.E.; Getz, G.; Gomez-Fernandez, C.; Gribbin, T.; Grimsby, J.; Gross, B.; Guin, R.; Gutschner, T.; Hadjipanayis, A.; Halaban, R.; Hanf, B.; Haussler, D.; Haydu, L.E.; Hayes, D.N.; Hayward, N.K.; Heiman, D.I.; Herbert, L.; Herman, J.G.; Hersey, P.; Hoadley, K.A.; Hodis, E.; Holt, R.A.; Hoon, D.S.B.; Hoppough, S.; Hoyle, A.P.; Huang, F.W.; Huang, M.; Huang, S.; Hutter, C.M.; Ibbs, M.; Iype, L.; Jacobsen, A.; Jakrot, V.; Janning, A.; Jeck, W.R.; Jefferys, S.R.; Jensen, M.A.; Jones, C.D.; Jones, S.J.M.; Ju, Z.; Kakavand, H.; Kang, H.; Kefford, R.F.; Khuri, F.R.; Kim, J.; Kirkwood, J.M.; Klode, J.; Korkut, A.; Korski, K.; Krauthammer, M.; Kucherlapati, R.; Kwong, L.N.; Kycler, W.; Ladanyi, M.; Lai, P.H.; Laird, P.W.; Lander, E.; Lawrence, M.S.; Lazar, A.J.; Łaźniak, R.; Lee, D.; Lee, J.E.; Lee, J.; Lee, K.; Lee, S.; Lee, W.; Leporowska, E.; Leraas, K.M.; Li, H.I.; Lichtenberg, T.M.; Lichtenstein, L.; Lin, P.; Ling, S.; Liu, J.; Liu, O.; Liu, W.; Long, G.V.; Lu, Y.; Ma, S.; Ma, Y.; Mackiewicz, A.; Mahadeshwar, H.S.; Malke, J.; Mallery, D.; Manikhas, G.M.; Mann, G.J.; Marra, M.A.; Matejka, B.; Mayo, M.; Mehrabi, S.; Meng, S.; Meyerson, M.; Mieczkowski, P.A.; Miller, J.P.; Miller, M.L.; Mills, G.B.; Moiseenko, F.; Moore, R.A.; Morris, S.; Morrison, C.; Morton, D.; Moschos, S.; Mose, L.E.; Muller, F.L.; Mungall, A.J.; Murawa, D.; Murawa, P.; Murray, B.A.; Nezi, L.; Ng, S.; Nicholson, D.; Noble, M.S.; Osunkoya, A.; Owonikoko, T.K.; Ozenberger, B.A.; Pagani, E.; Paklina, O.V.; Pantazi, A.; Parfenov, M.; Parfitt, J.; Park, P.J.; Park, W-Y.; Parker, J.S.; Passarelli, F.; Penny, R.; Perou, C.M.; Pihl, T.D.; Potapova, O.; Prieto, V.G.; Protopopov, A.; Quinn, M.J.; Radenbaugh, A.; Rai, K.; Ramalingam, S.S.; Raman, A.T.; Ramirez, N.C.; Ramirez, R.; Rao, U.; Rathmell, W.K.; Ren, X.; Reynolds, S.M.; Roach, J.; Robertson, A.G.; Ross, M.I.; Roszik, J.; Russo, G.; Saksena, G.; Saller, C.; Samuels, Y.; Sander, C.; Sander, C.; Sandusky, G.; Santoso, N.; Saul, M.; Saw, R.P.M.; Schadendorf, D.; Schein, J.E.; Schultz, N.; Schumacher, S.E.; Schwallier, C.; Scolyer, R.A.; Seidman, J.; Sekhar, P.C.; Sekhon, H.S.; Senbabaoglu, Y.; Seth, S.; Shannon, K.F.; Sharpe, S.; Sharpless, N.E.; Shaw, K.R.M.; Shelton, C.; Shelton, T.; Shen, R.; Sheth, M.; Shi, Y.; Shiau, C.J.; Shmulevich, I.; Sica, G.L.; Simons, J.V.; Sinha, R.; Sipahimalani, P.; Sofia, H.J.; Soloway, M.G.; Song, X.; Sougnez, C.; Spillane, A.J.; Spychała, A.; Stretch, J.R.; Stuart, J.; Suchorska, W.M.; Sucker, A.; Sumer, S.O.; Sun, Y.; Synott, M.; Tabak, B.; Tabler, T.R.; Tam, A.; Tan, D.; Tang, J.; Tarnuzzer, R.; Tarvin, K.; Tatka, H.; Taylor, B.S.; Teresiak, M.; Thiessen, N.; Thompson, J.F.; Thorne, L.; Thorsson, V.; Trent, J.M.; Triche, T.; J., Jr; Tsai, K.Y.; Tsou, P.; Van Den Berg, D.J.; Van Allen, E.M.; Veluvolu, U.; Verhaak, R.G.; Voet, D.; Voronina, O.; Walter, V.; Walton, J.S.; Wan, Y.; Wang, Y.; Wang, Z.; Waring, S.; Watson, I.R.; Weinhold, N.; Weinstein, J.N.; Weisenberger, D.J.; White, P.; Wilkerson, M.D.; Wilmott, J.S.; Wise, L.; Wiznerowicz, M.; Woodman, S.E.; Wu, C-J.; Wu, C-C.; Wu, J.; Wu, Y.; Xi, R.; Xu, A.W.; Yang, D.; Yang, L.; Yang, L.; Zack, T.I.; Zenklusen, J.C.; Zhang, H.; Zhang, J.; Zhang, W.; Zhao, X.; Zhu, J.; Zhu, K.; Zimmer, L.; Zmuda, E.; Zou, L. Genomic classification of cutaneous melanoma. Cell, 2015, 161(7), 1681-1696.
[http://dx.doi.org/10.1016/j.cell.2015.05.044] [PMID: 26091043]

Fitzpatrick, T.B. The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol., 1988, 124(6), 869-871.
[http://dx.doi.org/10.1001/archderm.1988.01670060015008] [PMID: 3377516]

Kefford, R.F.; Newton Bishop, J.A.; Bergman, W.; Tucker, M.A. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J. Clin. Oncol., 1999, 17(10), 3245-3251.
[http://dx.doi.org/10.1200/JCO.1999.17.10.3245] [PMID: 10506626]

Sun, X.; Kim, A.; Nakatani, M.; Shen, Y.; Liu, L. Distinctive molecular responses to ultraviolet radiation between keratinocytes and melanocytes. Exp. Dermatol., 2016, 25(9), 708-713.
[http://dx.doi.org/10.1111/exd.13057] [PMID: 27119462]

Gandini, S.; Sera, F.; Cattaruzza, M.S.; Pasquini, P.; Picconi, O.; Boyle, P.; Melchi, C.F. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur. J. Cancer, 2005, 41(1), 45-60.
[http://dx.doi.org/10.1016/j.ejca.2004.10.016] [PMID: 15617990]

Filosa, A.; Filosa, G. Actinic keratosis and squamous cell carcinoma: clinical and pathological features. G. Ital. Dermatol. Venereol., 2015, 150(4), 379-384.
[PMID: 26099352]

Bakshi, A.; Shafi, R.; Nelson, J.; Cantrell, W.C.; Subhadarshani, S.; Andea, A.; Athar, M.; Elmets, C.A. The clinical course of actinic keratosis correlates with underlying molecular mechanisms. Br. J. Dermatol., 2020, 182(4), 995-1002.
[http://dx.doi.org/10.1111/bjd.18338] [PMID: 31299087]

Javor, S.; Gasparini, G.; Biatta, C.M.; Cozzani, E.; Cabiddu, F.; Ravetti, J.L.; Vellone, V.G.; Parodi, A. P53 staining index and zonal staining patterns in actinic keratoses. Arch. Dermatol. Res., 2021, 313(4), 275-279.
[http://dx.doi.org/10.1007/s00403-020-02104-y] [PMID: 32642809]

Wang, W.; Edington, H.D.; Rao, U.N.M.; Jukic, D.M.; Wang, H.; Shipe-Spotloe, J.M.; Kirkwood, J.M. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy. J. Invest. Dermatol., 2008, 128(8), 1997-2002.
[http://dx.doi.org/10.1038/jid.2008.26] [PMID: 18305569]

Bosserhoff, A.K. Melanoma inhibitory activity (MIA): An important molecule in melanoma development and progression. Pigment Cell Res., 2005, 0(0)
[http://dx.doi.org/10.1111/j.1600-0749.2005.00274.x] [PMID: 16280006]

Carpi, S.; Polini, B.; Fogli, S.; Podestà, A.; Ylösmäki, E.; Cerullo, V.; Romanini, A.; Nieri, P. Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma. Expert Rev. Mol. Diagn., 2020, 20(1), 19-30.
[http://dx.doi.org/10.1080/14737159.2020.1696194] [PMID: 31747311]

Kelly, G.; Paulson, M.C.; Lahman, A.G. Chapuis; Isaac, B. Immunotherapy for skin cancer. Int. Immunol., 2019, 31, 465-475.

Bassiony, M.; Aluko, A.V.; Radosevich, J.A. Immunotherapy and Cancer. Preccision Medicine in Oncology, 2021, 1, 133-187.

Feng, X. Novel target therapy and immunotherapy for skin cancer. US Pharm., 2012, 37(11), 7-11.

Bridge, J.A.; Lee, J.C.; Daud, A.; Wells, J.W.; Bluestone, J.A. Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer. Front. Med., 2018, 5, 351.
[http://dx.doi.org/10.3389/fmed.2018.00351] [PMID: 30631766]

Emens, L.A.; Ascierto, P.A.; Darcy, P.K.; Demaria, S.; Eggermont, A.M.M.; Redmond, W.L.; Seliger, B.; Marincola, F.M. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur. J. Cancer, 2017, 81, 116-129.
[http://dx.doi.org/10.1016/j.ejca.2017.01.035] [PMID: 28623775]

Lim, S.; Park, J.; Shim, M.K.; Um, W.; Yoon, H.Y.; Ryu, J.H.; Lim, D.K.; Kim, K. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics, 2019, 9(25), 7906-7923.
[http://dx.doi.org/10.7150/thno.38425] [PMID: 31695807]

Martin, J.D.; Cabral, H.; Stylianopoulos, T.; Jain, R.K. Improving cancer immunotherapy using nanomedicines: Progress, opportunities and challenges. Nat. Rev. Clin. Oncol., 2020, 17(4), 251-266.
[http://dx.doi.org/10.1038/s41571-019-0308-z] [PMID: 32034288]

Wilken, R.; Criscito, M.; Pavlick, A.C.; Stevenson, M.L.; Carucci, J.A. Current research in melanoma and aggressive nonmelanoma skin cancer. Facial Plast. Surg., 2020, 36(2), 200-210.
[http://dx.doi.org/10.1055/s-0040-1709118] [PMID: 32413929]

Twomey, J.D.; Zhang, B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J., 2021, 23(2), 39.
[http://dx.doi.org/10.1208/s12248-021-00574-0] [PMID: 33677681]

Shalhout, S.Z.; Emerick, K.S.; Kaufman, H.L.; Miller, D.M. Immunotherapy for non-melanoma skin cancer. Curr. Oncol. Rep., 2021, 23(11), 125.
[http://dx.doi.org/10.1007/s11912-021-01120-z] [PMID: 34448958]

Esfahani, K.; Roudaia, L.; Buhlaiga, N.; Del Rincon, S.V.; Papneja, N.; Miller, W.H. Jr A review of cancer immunotherapy: From the past, to the present, to the future. Curr. Oncol., 2020, 27(S12), 87-97.
[http://dx.doi.org/10.3747/co.27.5223] [PMID: 32368178]

Simões, M.C.F.; Sousa, J.J.S.; Pais, A.A.C.C. Skin cancer and new treatment perspectives: A review. Cancer Lett., 2015, 357(1), 8-42.
[http://dx.doi.org/10.1016/j.canlet.2014.11.001] [PMID: 25444899]

Ghahartars, M.; Sedaghat, F.; Khajavi, E.; Nejat, A.A.; Malekzadeh, M.; Ghaderi, A.; Fattahi, M.J. Investigation of IL-17A serum levels in patients with nonmelanoma skin cancer. Dermatol. Res. Pract., 2021, 2021, 1-5.
[http://dx.doi.org/10.1155/2021/5540163] [PMID: 34239554]

Wong, A.N.M.; McArthur, G.A.; Hofman, M.S.; Hicks, R.J. The Advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur. J. Nucl. Med. Mol. Imaging, 2017, 44(S1), 67-77.
[http://dx.doi.org/10.1007/s00259-017-3691-7] [PMID: 28389693]

Brown, C. Difficult skin cancers: Clinicopathologic features and management. Proc. Bayl. Univ. Med. Cent., 1993, 6(2), 9-12.
[http://dx.doi.org/10.1080/08998280.1993.11929814]

Pizzimenti, S.; Dianzani, C.; Zara, G.P.; Ferretti, C.; Rossi, F.; Gigliotti, C.L.; Daga, M.; Ciamporcero, E.S.; Maina, G.; Barrera, G. Challenges and opportunities of nanoparticle-based theranostics in skin cancer. Nanoscience in dermatology, 2016, 177-188.
[http://dx.doi.org/10.1016/B978-0-12-802926-8.00014-8]

Apalla, Z.; Nashan, D.; Weller, R.B.; Castellsagué, X. Skin cancer: Epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol. Ther., 2017, 7(S1), 5-19.
[http://dx.doi.org/10.1007/s13555-016-0165-y] [PMID: 28150105]

Nguyen, K.; Geller, A.; Lin, J.Y. Improvements and continued challenges in the early detection of skin cancers. Expert. Rev. Dermatol., 2012, 7(5), 459-471.
[http://dx.doi.org/10.1586/edm.12.46]

Harwansh, R.K.; Deshmukh, R. Breast cancer: An insight into its inflammatory, molecular, pathological and targeted facets with update on investigational drugs. Crit. Rev. Oncol. Hematol., 2020, 154, 103070.
[http://dx.doi.org/10.1016/j.critrevonc.2020.103070] [PMID: 32871325]

Borgheti-Cardoso, L.N.; Viegas, J.S.R.; Silvestrini, A.V.P.; Caron, A.L.; Praça, F.G.; Kravicz, M.; Bentley, M.V.L.B. Nanotechnology approaches in the current therapy of skin cancer. Adv. Drug Deliv. Rev., 2020, 153, 109-136.
[http://dx.doi.org/10.1016/j.addr.2020.02.005] [PMID: 32113956]

Gunturi, A.; McDermott, D.F. Nivolumab for the treatment of cancer. Expert Opin. Investig. Drugs, 2015, 24(2), 253-260.
[http://dx.doi.org/10.1517/13543784.2015.991819] [PMID: 25494679]

Huang, P.W.; Chang, J.W.C. Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomed. J., 2019, 42(5), 299-306.
[http://dx.doi.org/10.1016/j.bj.2019.09.002] [PMID: 31783990]

Albittar, A.A.; Alhalabi, O.; Glitza Oliva, I.C. Immunotherapy for melanoma. Adv. Exp. Med. Biol., 2020, 1244, 51-68.
[http://dx.doi.org/10.1007/978-3-030-41008-7_3] [PMID: 32301010]

Dhupal, M.; Chowdhury, D. Phytochemical-based nanomedicine for advanced cancer theranostics: Perspectives on clinical trials to clinical use. Int. J. Nanomedicine, 2020, 15(15), 9125-9157.
[http://dx.doi.org/10.2147/IJN.S259628] [PMID: 33244231]

Anassi, E.; Ndefo, U.A. Sipuleucel-T (provenge) injection: The first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. PT., 2011, 36(4), 197-202.
[PMID: 21572775]

Kang, A.; Zhao, D.; Yeh, J.J.; Lee, D.J. Updates on immunotherapy for the treatment of skin cancer. Curr. Dermatol. Rep., 2018, 7(4), 311-320.
[http://dx.doi.org/10.1007/s13671-018-0246-5]

Benmebarek, M.R.; Karches, C.; Cadilha, B.; Lesch, S.; Endres, S.; Kobold, S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int. J. Mol. Sci., 2019, 20(6), 1283.
[http://dx.doi.org/10.3390/ijms20061283] [PMID: 30875739]

Smith, Aaron J.; Oertle, John; Warren, Dan Prato, Dino Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective. J. Cell. Immunother, 2016, 2(2), 59-68.
[http://dx.doi.org/10.1016/j.jocit.2016.08.001]

Zugmaier, G.; Klinger, M.; Schmidt, M.; Subklewe, M. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies. Mol Immunol, 2015, 67(2PtA), 58-66.
[http://dx.doi.org/10.1016/j.molimm.2015.02.033] [PMID: 25883042]

Registrar Corp. Available from: https://www.fda.gov

Available from: https://www.cdsc.gov